Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 20
- Registration Number
- NCT00203229
- Locations
- 🇺🇸
Jefferson Headache Center, Philadelphia, Pennsylvania, United States
Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT00181844
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Maintenance Treatment of Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-05-17
- Target Recruit Count
- 86
- Registration Number
- NCT00183469
Lamotrigine Monotherapy in Pediatric Bipolar Disorder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 48
- Registration Number
- NCT00176228
- Locations
- 🇺🇸
NPI, University of Illinois at Chicago, Chicago, Illinois, United States
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT00177567
- Locations
- 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Study of Efficacy of Lamotrigine in Therapy of Bronchial Asthma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Centre of Chinese Medicine, Georgia
- Target Recruit Count
- 76
- Registration Number
- NCT00153244
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00144872
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Hormone Profiles in Adults With Newly Diagnosed Epilepsy
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 80
- Registration Number
- NCT00137709
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇭🇰United Christian Hospital, Kowloon, Hong Kong
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
- Conditions
- Interventions
- First Posted Date
- 2004-07-27
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 453
- Registration Number
- NCT00088452
- Locations
- 🇺🇸
Mattel Children's Hospital at UCLA, Los Angeles, California, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Children's Hospital, Inc., PCTI, Columbus, Ohio, United States
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
- Conditions
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT00086593
- Locations
- 🇬🇧
GSK Investigational Site, Hull, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.